AXIM Biotechnologies, Inc.
AXIM
$0.003
$0.000.00%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 254.96% | 423.93% | 347.19% | 465.57% | 103.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 254.96% | 423.93% | 347.19% | 465.57% | 103.10% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 248.09% | 423.93% | 347.19% | 465.57% | 103.10% |
| SG&A Expenses | -43.48% | -46.33% | -45.18% | -33.68% | -36.71% |
| Depreciation & Amortization | 0.61% | 0.49% | 0.28% | -60.47% | -74.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.15% | -40.43% | -40.14% | -38.94% | -45.64% |
| Operating Income | 40.13% | 42.22% | 40.89% | 39.54% | 45.91% |
| Income Before Tax | 56.09% | 19.22% | -29.10% | 47.30% | 35.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.09% | 19.22% | -29.10% | 47.30% | 35.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.09% | 19.22% | -29.10% | 47.31% | 35.70% |
| EBIT | 40.13% | 42.22% | 40.89% | 39.54% | 45.91% |
| EBITDA | 45.18% | 47.00% | 45.02% | 34.02% | 37.18% |
| EPS Basic | 66.09% | 35.29% | 6.98% | 64.66% | 56.44% |
| Normalized Basic EPS | 75.43% | 42.73% | 8.07% | 26.57% | 21.89% |
| EPS Diluted | 55.04% | 20.19% | -5.37% | 59.10% | 54.38% |
| Normalized Diluted EPS | 73.70% | 40.45% | 5.83% | 24.83% | 21.89% |
| Average Basic Shares Outstanding | 27.60% | 31.49% | 37.79% | 40.93% | 39.78% |
| Average Diluted Shares Outstanding | 58.36% | 65.26% | 74.99% | 81.23% | 39.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
